

THOMSON REUTERS INTEGRITY: BIOMARKERS MODULE



DISCOVER THE BIOMARKERS

- Associated with a disease and confidence-level for each biomarker use
- Affected by modifying target activity
- Available for safety and toxicity use
- For patient stratification
- With the utility to move your compound from discovery to the clinic

WHO CAN BENEFIT

- Discovery Biologists
- Pre-clinical Scientists
- Pharmacologists
- Toxicologists
- Clinical Researchers
- Translational Researchers
- Biomarker Specialists
- Informaticians

THE NEW STANDARD IN BIOMARKER RESEARCH

The *Biomarkers Module* of *Thomson Reuters Integrity*SM provides a wealth of reliable, high-quality, continually updated information supporting [biomarker research](#) at every stage of drug R&D including:

- Target identification
- Proof of mechanism
- Proof of concept
- Treatment / safety monitoring
- Outcome measurement

The *Biomarkers Module* is the first biomarker database to provide standardized terminology and to classify biomarkers reliably into lifecycle phases and disciplines.

It is designed to help you make better, more informed decisions as you strive to improve cost efficiency, predict and minimise risk and avoid late stage attrition.

RELIABLE DATA, PLACED IN CONTEXT FOR YOU TO ASSESS AT A GLANCE

Drawing on data from a host of sources, such as literature, patents, conferences and medical meetings, the *Biomarkers Module* is reliable in content, rich in analysis and backed up by rigorous editorial standards.

Each biomarker use is assigned to a lifecycle stage, from discovery to widespread clinical acceptance, so you can assess at a glance the most appropriate biomarker for your project.

Integrity allows you to contextualize and assess the relative importance of each biomarker by exploring the associated drugs, targets and genes.

The *Biomarkers Module* covers a wide range of biomarker types from genomic, proteomic and

biochemical to cellular and physiological. Imaging biomarkers are a recent addition complete with new standard terminology applied to imaging techniques.

Therapy areas are continually being expanded and now cover:

- Oncology
- Cardiovascular disease
- Diabetes
- Immunology
- Respiratory diseases
- Neurological disorders
- Pain
- Infectious disease
- Musculoskeletal and connective tissue disorders
- Endocrine disease

The *Biomarkers Module* includes biomarkers having clinical utility, those that have been used in a pre-clinical setting – possible candidates for translation into the clinic – as well as markers with newly emerging uses which can provide new insight into your biomarker research.

Each manually curated record in the *Biomarkers Module* is enriched still further with links to supporting and refuting source documents and includes:

- the biomarker's name and synonyms
- the biological entities/processes involved
- the associated drugs and mechanisms of action
- the associated gene variants
- its roles or utilities
- measurement techniques
- FDA approved kits

Also available as an XML feed for your in-house solutions.



BIOMARKERS MODULE DEVELOPMENT

May 2008


Biomarkers: **505**

Uses: **3,500**

January 2010

Biomarkers: **4,000**

Uses: **60,000**



**DISCOVERY BIOLOGISTS
HELPING YOU TO:**

- Learn the biology of the disease you're working on, and understand the current research situation regarding biomarkers in your therapy area.
- Choose the biomarker that will give early indications on whether modifying a potential target has a positive outcome on the disease process.

**PRE-CLINICAL SCIENTISTS
HELPING YOU TO:**

- Find the biomarkers that show the effects of your compound on the disease state.
- Select suitable biomarkers for use in safety and efficacy studies to give early indication of toxicity and proof of concept.

**CLINICAL RESEARCHERS
HELPING YOU TO:**

- Find the population that will respond best to the particular treatment.
- Know which biomarkers to use to improve can improve the design and efficiency of your studies and improve your probability of success.

**TRANSLATIONAL RESEARCHERS
HELPING YOU TO:**

- Connect experimental research and clinical studies for pivotal insights.
- Assign the right biomarker to the right project as early as possible.

**Healthcare & Science
Regional Offices**

North America

Philadelphia +1 800 336 4474
+1 215 386 0100
San Diego +1 858 273 8616

Latin America

+55 11 8370 9845

Europe, Middle East and Africa

Barcelona +34 93 459 2220
London +44 20 7433 4000

Asia Pacific

Singapore +65 6775 5088
Tokyo +81 3 5218 6500

Contact us to find out more about the *Biomarkers Module* or visit go.thomsonreuters.com/integrity

For a complete office list visit:
science.thomsonreuters.com/contact

